Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids.

[1]  H. Kelly,et al.  Comparison of Inhaled Corticosteroids , 1998, The Annals of pharmacotherapy.

[2]  V. Brusasco,et al.  Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. , 1998, American journal of respiratory and critical care medicine.

[3]  J. Drazen,et al.  Inflammation and airway function in asthma: what you see is not necessarily what you get. , 1998, American journal of respiratory and critical care medicine.

[4]  L. S. Hill,et al.  A comparison of the performance of two modern multidose dry powder asthma inhalers. , 1998, Respiratory medicine.

[5]  T. Harris,et al.  Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. , 1998, Respiratory medicine.

[6]  J. Paulson,et al.  Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. , 2003, British journal of clinical pharmacology.

[7]  H. Derendorf.  Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. , 1997, Respiratory medicine.

[8]  H. Möllmann,et al.  Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model , 1997, Journal of clinical pharmacology.

[9]  B. Meibohm,et al.  Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation , 1997, Journal of clinical pharmacology.

[10]  L. Edwards,et al.  Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. , 1997, The Journal of allergy and clinical immunology.

[11]  R. Pauwels,et al.  Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. , 1997, The European respiratory journal.

[12]  M. Everard,et al.  Lung deposition from the Turbuhaler in children with cystic fibrosis. , 1997, The European respiratory journal.

[13]  S. Pedersen,et al.  A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. , 1997, The Journal of allergy and clinical immunology.

[14]  J. Baskerville,et al.  Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. , 1997, The Journal of allergy and clinical immunology.

[15]  P. O'Byrne,et al.  A comparison of the efficacy and safety of inhaled corticosteroids in asthma , 1997, Allergy.

[16]  H. Bisgaard.  Delivery of inhaled medication to children. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.

[17]  A. Bye,et al.  Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. , 2003, British journal of clinical pharmacology.

[18]  S. Szefler,et al.  Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. , 1996, The Journal of allergy and clinical immunology.

[19]  R. Sorva,et al.  Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). , 1996, The European respiratory journal.

[20]  P. Swinburn,et al.  A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation , 1996, Mediators of inflammation.

[21]  J. Baskerville,et al.  A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations. , 1996, The Journal of allergy and clinical immunology.

[22]  P. Barnes,et al.  Mechanisms of action of glucocorticoids in asthma. , 1996, American journal of respiratory and critical care medicine.

[23]  I. Adcock,et al.  Steroid Resistance in Asthma: Molecular Mechanisms , 1996 .

[24]  E. Israel,et al.  Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. , 1996, American journal of respiratory and critical care medicine.

[25]  B. Lipworth.  Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. , 1996, Pulmonary pharmacology.

[26]  C. Pickering,et al.  267 A comparison of fluticasone propionate via Diskus™(Accuhaler™) inhaler and budesonide via Turbuhaler™ inhaler in adult asthmatics , 1996 .

[27]  M. Johnson,et al.  Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. , 1996, The Journal of allergy and clinical immunology.

[28]  D. Geddes,et al.  Inhaled corticosteroids: benefits and risks. , 1996, The Journal of asthma : official journal of the Association for the Care of Asthma.

[29]  H. Möllmann,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration , 1995, Journal of clinical pharmacology.

[30]  S. Holgate,et al.  Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. , 1995, The European respiratory journal.

[31]  B. Olsson.  Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? , 1995, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[32]  L. Thorsson.  Influence of inhaler systems on systemic availability, with focus on inhaled corticosteroids. , 1995, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[33]  M. Tjwa.  Budesonide inhaled via Turbuhaler: a more effective treatment for asthma than beclomethasone dipropionate via Rotahaler. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[34]  S. Szefler,et al.  Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. , 1995, American journal of respiratory and critical care medicine.

[35]  E. Bateman,et al.  High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. , 1995, The European respiratory journal.

[36]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[37]  B. Lipworth,et al.  New perspectives on inhaled drug delivery and systemic bioactivity , 1995 .

[38]  R. Fuller.  The DiskusTM: A New Multi-Dose Powder Device – Efficacy and Comparison with TurbuhalerTM , 1995 .

[39]  S. Pedersen,et al.  Budesonide treatment of moderate and severe asthma in children: a dose-response study. , 1995, The Journal of allergy and clinical immunology.

[40]  O. Selroos,et al.  Clinical efficacy of budesonide Turbuhaler® compared with that of beclomethasone dipropionate pMDI with volumatic spacer , 1994, Allergy.

[41]  A. Gulsvik,et al.  High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society. , 1994, The European respiratory journal.

[42]  D. Postma,et al.  Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. , 1994, Thorax.

[43]  P. Högger,et al.  Binding kinetics of fluticasone propionate to the human glucocorticoid receptor , 1994, Steroids.

[44]  M. Zureik,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. , 1994, The European respiratory journal.

[45]  R. Dockhorn,et al.  Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. , 1994, The Journal of allergy and clinical immunology.

[46]  C. O’Callaghan,et al.  Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation? , 1994, Thorax.

[47]  T. Haahtela,et al.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.

[48]  P. Leblanc,et al.  A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma , 1994, Allergy.

[49]  L. Borgström,et al.  Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. , 1994, The European respiratory journal.

[50]  J. Hébert,et al.  Evaluation of fluticasone propionate (500 μg day−1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day−1) administered by pressurized inhaler , 1993 .

[51]  R. Dahl,et al.  A Dose-Ranging Study of Fluticasone Propionate in Adult Patients With Moderate Asthma , 1993 .

[52]  M. Hughes,et al.  Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group. , 1993, The American review of respiratory disease.

[53]  S. Szefler,et al.  Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. , 1993, Journal of immunology.

[54]  G. Crompton,et al.  Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. , 1993, Thorax.

[55]  M. Gold,et al.  Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. , 1993, Archives of disease in childhood.

[56]  L. Fabbri,et al.  Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. , 1993, Thorax.

[57]  S. Pedersen,et al.  Importance of the inhalation device on the effect of budesonide. , 1993, Archives of disease in childhood.

[58]  G. Marone,et al.  A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. , 1993, The European respiratory journal.

[59]  B. Davies.  A comparison of beclomethasone dipropionate and budesonide in the treatment of asthma. , 1993, The British journal of clinical practice.

[60]  S. Tunn,et al.  Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids , 1993, Journal of clinical pharmacology.

[61]  L. Frølund,et al.  High‐dose inhaled steroids in the management of asthma A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and the adrenal function , 1992, Allergy.

[62]  O. Selroos,et al.  Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. , 1991, Thorax.

[63]  E. Juniper,et al.  Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. , 1991, The Journal of allergy and clinical immunology.

[64]  G. H. Phillipps.  Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. , 1990, Respiratory medicine.

[65]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[66]  G. Crompton,et al.  Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? , 1990, Thorax.

[67]  W. Jusko.  Corticosteroid Pharmacodynamics: Models for a Broad Array of Receptor‐Mediated Pharmacologic Effects , 1990, Journal of clinical pharmacology.

[68]  S. Pedersen,et al.  Influence of inspiratory flow rate upon the effect of a Turbuhaler. , 1990, Archives of disease in childhood.

[69]  P. Godard,et al.  High doses of inhaled corticosteroids in unstable chronic asthma. A multicenter, double-blind, placebo-controlled study. , 1989, The American review of respiratory disease.

[70]  K. Nikander,et al.  Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler® , 1989, Allergy.

[71]  P. Bamberg,et al.  Comparison of inhaled budesonide with oral prednisolone at two dose-levels commonly used for the treatment of moderate asthma. , 1989, The European respiratory journal.

[72]  W. Jenner,et al.  Immunoassay of Beclomethasone 17,21-Dipropionate and Metabolites , 1988 .

[73]  H. Sluiter,et al.  Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. , 1988, The American review of respiratory disease.

[74]  S. Newman,et al.  Aerosol deposition considerations in inhalation therapy. , 1985, Chest.

[75]  R. Pauwels,et al.  Kinetics of the epimeric glucocorticoid budesonide , 1984, Clinical pharmacology and therapeutics.

[76]  J. Gustafsson,et al.  Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. , 1984, Molecular pharmacology.

[77]  R. Pauwels,et al.  Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. , 1982, European journal of respiratory diseases. Supplement.

[78]  S. Johansson,et al.  Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. , 1982, European journal of respiratory diseases. Supplement.

[79]  R. E. Jones,et al.  Correlation of flunisolide plasma levels to eosinopenic response in humans. , 1980, The Journal of allergy and clinical immunology.

[80]  E. W. Swenson,et al.  Flunisolide metabolism and dynamics of a metabolite , 1980, Clinical pharmacology and therapeutics.

[81]  R. Stoughton,et al.  Method for Comparing Percutaneous Absorption of Steroids , 1962 .

[82]  A. Mckenzie.  Percutaneous Absorption of Steroids , 1962 .